02Oct/13

Cellmid's midkine antibodies show effectiveness against cancer – Proactive Investors Australia


Proactive Investors Australia

Cellmid’s midkine antibodies show effectiveness against cancer
Proactive Investors Australia
“We have postulated for some time that MK antibodies would have anti-cancer activities, via multiple mechanisms of action, and it is pleasing to see this confirmed in our own studies with our proprietary MK antibodies.” Cellmid’s cancer antibody

and more »

02Oct/13

New Lymphoma Study Findings Recently Were Reported by Researchers at … – HispanicBusiness.com

New Lymphoma Study Findings Recently Were Reported by Researchers at
HispanicBusiness.com
Twenty-four patients were enrolled prospectively and were treated with unlabeled rituximab 70 mg and a therapeutic activity (median 7.3 GBq) of I-131 –rituximab.” The news correspondents obtained a quote from the research from the Institute of

and more »

02Oct/13

Researchers at Department of Haematology and Oncology Report Findings in … – HispanicBusiness.com

Researchers at Department of Haematology and Oncology Report Findings in
HispanicBusiness.com
Their experience showed that this drug is effective and manageable even when reused in both settings: chronic lymphocytic leukemia and non-Hodgkin’s lymphomas combined with rituximab and/or mitoxantrone. The slow evolution in the treatment of patients 

02Oct/13

CRSA Committed to Advancing Surgeon Training in Robotic Surgery – EON: Enhanced Online News (press release)

CRSA Committed to Advancing Surgeon Training in Robotic Surgery
EON: Enhanced Online News (press release)
This technology has dramatically improved the utilization of minimally invasive surgery across several fields including urology, gynecology, thoracic, cardiac, colon, pancreas and transplant surgery. “As robotic surgery continues to evolve, it is

02Oct/13

Studies from West Virginia University Have Provided New Information about … – HispanicBusiness.com

Studies from West Virginia University Have Provided New Information about
HispanicBusiness.com
The news reporters obtained a quote from the research from West Virginia University , “Randomized trials comparing the addition (or not) of rituximab to high-dose therapy regimens are lacking. No benefit of standard-dose radio-immunotherapy-based